Literature DB >> 11063115

Adenoviral gene transfer of nitric oxide synthase increases cerebral blood flow in rats.

J C Lüders1, C C Weihl, G Lin, G Ghadge, M Stoodley, R P Roos, R L Macdonald.   

Abstract

OBJECTIVE: Depletion of nitric oxide may play a role in the development of vasospasm after aneurysmal subarachnoid hemorrhage. Replenishment of nitric oxide might be a useful treatment for vasospasm. Using rats, we performed intracisternal injections of replication-defective adenovirus containing the endothelial nitric oxide synthase (eNOS) gene and determined the localization of and effect on cerebral blood flow of transgene expression.
METHODS: Rats underwent baseline measurement of cortical cerebral blood flow using laser Doppler flowmetry. Replication-defective adenovirus containing the Escherichia coli LacZ gene (Ad327beta-Gal, n = 2/time point) or the bovine eNOS gene (AdCD8-NOS, n = 4/time point) or physiological saline solution was injected into the cisterna magna. Cerebral blood flow was measured 1, 2, 4, 7, or 14 days later, and the animals were killed. Expression of beta-galactosidase activity from the LacZ gene was examined by histochemical staining and that of eNOS was examined by polymerase chain reaction assays of messenger ribonucleic acid. Brains were histopathologically examined for inflammation.
RESULTS: Beta-galactosidase activity was observed throughout the leptomeninges and in some cells in the adventitia of small subarachnoid blood vessels in the Ad327beta-Gal-injected rats. Messenger ribonucleic acid for eNOS was detected in the leptomeninges and brainstem 1 and 2 days after injection of AdCD8-NOS. Rats injected with Ad327beta-Gal or physiological saline solution exhibited decreased cerebral blood flow beginning 2 days after virus injection and lasting up to 14 days after injection. Rats injected with AdCD8-NOS developed significant transient increases in cerebral blood flow 2 days after virus injection, followed by slight decreases in blood flow. There was inflammation in the subarachnoid space of all animals; the inflammation was qualitatively worse in animals injected with Ad327beta-Gal, compared with rats injected with AdCD8-NOS or saline solution.
CONCLUSION: Intracisternal injection of replication-defective adenovirus containing the eNOS gene can transiently increase cerebral blood flow.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063115     DOI: 10.1097/00006123-200011000-00039

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  5 in total

Review 1.  Role of endothelial nitric oxide in cerebrovascular regulation.

Authors:  Dmitriy N Atochin; Paul L Huang
Journal:  Curr Pharm Biotechnol       Date:  2011-09       Impact factor: 2.837

Review 2.  Cerebral vasospasm following subarachnoid hemorrhage: time for a new world of thought.

Authors:  Ryszard M Pluta; Jacob Hansen-Schwartz; Jens Dreier; Peter Vajkoczy; R Loch Macdonald; Shigeru Nishizawa; Hideotoshi Kasuya; George Wellman; Emanuela Keller; Alois Zauner; Nicholas Dorsch; Joseph Clark; Shigeki Ono; Talat Kiris; Peter Leroux; John H Zhang
Journal:  Neurol Res       Date:  2009-03       Impact factor: 2.448

3.  Targeted overexpression of endothelial nitric oxide synthase in endothelial cells improves cerebrovascular reactivity in Ins2Akita-type-1 diabetic mice.

Authors:  Saurav B Chandra; Sumathy Mohan; Bridget M Ford; Lei Huang; Preethi Janardhanan; Kaiwalya S Deo; Linlin Cong; Eric R Muir; Timothy Q Duong
Journal:  J Cereb Blood Flow Metab       Date:  2015-10-26       Impact factor: 6.200

Review 4.  Metamorphosis of subarachnoid hemorrhage research: from delayed vasospasm to early brain injury.

Authors:  Fatima A Sehba; Ryszard M Pluta; John H Zhang
Journal:  Mol Neurobiol       Date:  2010-12-15       Impact factor: 5.590

5.  Tooth loss, cognitive impairment and chronic cerebral ischemia.

Authors:  Qian Pang; Qianqian Wu; Xingxue Hu; Jianjun Zhang; Qingsong Jiang
Journal:  J Dent Sci       Date:  2019-10-19       Impact factor: 2.080

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.